Collegium to Participate in H.C. Wainwright Global Investment Conference
May 17, 2022 08:00 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that management will...
Collegium Reports First Quarter 2022 Financial Results
May 10, 2022 16:01 ET
|
Collegium Pharmaceutical, Inc.
- Generated Net Revenue of $83.8 Million - - Completed BDSI Acquisition; On Track to Exceed Targeted Run Rate Synergies of at Least $75 Million - - Resolved All Opioid-Industry Litigation - -...
Collegium to Host Conference Call to Discuss First Quarter 2022 Financial Results
April 26, 2022 16:00 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that the Company will...
Collegium to Participate in Upcoming Needham Healthcare Conference
April 07, 2022 16:47 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that management will...
Collegium Appoints Neil McFarlane to its Board of Directors
April 06, 2022 08:00 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced the appointment of Neil...
Collegium Provides 2022 Financial Guidance
April 05, 2022 08:00 ET
|
Collegium Pharmaceutical, Inc.
– Total Product Revenues Expected in the Range of $450.0 million to $465.0 million – – Adjusted Operating Expenses Expected in the Range of $130.0 million to $140.0 million – – Adjusted EBITDA...
Collegium Announces Master Settlement Agreement Resolving Pending Opioid-Related Litigation
March 30, 2022 08:01 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., March 30, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the execution of a Master Settlement Agreement resolving all 27 pending...
Collegium Completes the Acquisition of BDSI
March 22, 2022 17:01 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) (“Collegium”) today announced that it has completed the acquisition of BioDelivery Sciences...
Collegium Reports Fourth Quarter and Full-Year 2021 Financial Results
February 24, 2022 16:01 ET
|
Collegium Pharmaceutical, Inc.
– BDSI Acquisition Expected to Close Late Q1 2022 – – 2022 Revenue Guidance of $315-$330 Million, Growth Driven by Xtampza ER – – Full-Year Net Income of $71.5 Million and Full-Year Adjusted EBITDA...
Collegium to Acquire BioDelivery Sciences Broadening Pain Portfolio
February 14, 2022 06:30 ET
|
Collegium Pharmaceutical, Inc.
- Expected to be Immediately and Highly Accretive Driven by Identified Annual Synergies of at Least $75 Million - - Will Diversify Revenue Growth and Accelerate Cash Flow Generation - - Addition of...